These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 1366624)
61. Advances in monoclonal antibody therapy of cancer. LoBuglio AF; Saleh MN Am J Med Sci; 1992 Sep; 304(3):214-24. PubMed ID: 1476160 [TBL] [Abstract][Full Text] [Related]
62. Targeted toxins begin to live up to early expectations. Thompson T J Natl Cancer Inst; 2001 May; 93(10):736-8. PubMed ID: 11353778 [No Abstract] [Full Text] [Related]
63. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Keppler-Hafkemeyer A; Kreitman RJ; Pastan I Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457 [TBL] [Abstract][Full Text] [Related]
64. The emerging role of immunotoxins in leukemia and lymphoma. Winkler U; Barth S; Schnell R; Diehl V; Engert A Ann Oncol; 1997; 8 Suppl 1():139-46. PubMed ID: 9187448 [TBL] [Abstract][Full Text] [Related]
65. Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS. Vitetta ES J Clin Immunol; 1990 Nov; 10(6 Suppl):15S-18S. PubMed ID: 2081785 [TBL] [Abstract][Full Text] [Related]
66. Bacterial Toxins for Cancer Therapy. Zahaf NI; Schmidt G Toxins (Basel); 2017 Jul; 9(8):. PubMed ID: 28788054 [TBL] [Abstract][Full Text] [Related]
70. Enhancement of immunotoxin activity using chemical and biological reagents. Wu M Br J Cancer; 1997; 75(9):1347-55. PubMed ID: 9155057 [TBL] [Abstract][Full Text] [Related]
72. Synthesis and testing of antibody-antifolate conjugates for drug targeting. Ghose T; Blair AH; Kralovec J; Mammen M; Uadia PO Targeted Diagn Ther; 1988; 1():81-122. PubMed ID: 2979064 [No Abstract] [Full Text] [Related]
73. Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy. Gilabert-Oriol R; Weng A; Mallinckrodt Bv; Melzig MF; Fuchs H; Thakur M Curr Pharm Des; 2014; 20(42):6584-643. PubMed ID: 25341935 [TBL] [Abstract][Full Text] [Related]
74. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
75. Immunotoxins: a clinical review of their use in the treatment of malignancies. Hertler AA; Frankel AE J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183 [TBL] [Abstract][Full Text] [Related]
76. Immunotoxins, ligand-toxin conjugates and molecular targeting. Soria M Pharmacol Res; 1989; 21 Suppl 2():35-46. PubMed ID: 2698471 [TBL] [Abstract][Full Text] [Related]
77. Immunotoxins: status and prospects. Spooner RA; Lord JM Trends Biotechnol; 1990 Jul; 8(7):189-93. PubMed ID: 1366624 [TBL] [Abstract][Full Text] [Related]
78. Redesigning nature's poisons to create anti-tumor reagents. Vitetta ES; Fulton RJ; May RD; Till M; Uhr JW Science; 1987 Nov; 238(4830):1098-104. PubMed ID: 3317828 [TBL] [Abstract][Full Text] [Related]